Increase in visceral adipose tissue and altered metabolic profile in transgender men but not in transgender women one year after starting gender-affirming hormonal therapy.
Clément Larose, Caroline Samhani, Pierre Consolandi, Eva Feigerlova
{"title":"Increase in visceral adipose tissue and altered metabolic profile in transgender men but not in transgender women one year after starting gender-affirming hormonal therapy.","authors":"Clément Larose, Caroline Samhani, Pierre Consolandi, Eva Feigerlova","doi":"10.1007/s12020-025-04310-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Increase in body fat and dyslipidemia have been reported in persons receiving gender-affirming hormone therapy (GAHT). However, little is known whether these changes are associated with a pro-inflammatory state.</p><p><strong>Objective: </strong>To study the relationship between changes in body composition, cardiometabolic parameters and systemic inflammatory indices in transgender persons at baseline and one year after starting GAHT.</p><p><strong>Method: </strong>A single center retrospective study including 50 assigned female at birth (AFAB) (median age 21.5 years) and 37 assigned male at birth (AMAB) persons (median age 29 years) with data separated by a 1-year period.</p><p><strong>Results: </strong>Testosterone therapy in AFAB persons led to a significant increase in VAT (P = 0.0006), trunk/limb ratio (P < 0.001), uric acid (P < 0.001), LDL-cholesterol (P < 0.05) and a significant decrease in HDL-cholesterol (P < 0.05). There were no changes in systemic inflammatory indices. Results of the final regression models indicated that increase in uric acid explained 33.2% of the variation in VAT [F(1,15) = 7.458; adjusted R square 0.332; P = 0.015]. In AMAB persons receiving GAHT, we observed an increase in total body fat (P = 0.002), fat mass index (P = 0.001) and HDL cholesterol (P < 0.05). The aspartate transaminase to lymphocyte ratio index decreased (P < 0.05) one year after the start of treatment.</p><p><strong>Conclusion: </strong>GAHT in the AFAB persons led to a significant increase in VAT and altered metabolic profile. There were no changes in systemic inflammatory indices. The AMAB people presented a non-deleterious cardiometabolic phenotype.</p><p><strong>Clinical trial registration: </strong>The study is registered at ClinicalTrials.gov (NCT04508231).</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"901-909"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04310-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Increase in body fat and dyslipidemia have been reported in persons receiving gender-affirming hormone therapy (GAHT). However, little is known whether these changes are associated with a pro-inflammatory state.
Objective: To study the relationship between changes in body composition, cardiometabolic parameters and systemic inflammatory indices in transgender persons at baseline and one year after starting GAHT.
Method: A single center retrospective study including 50 assigned female at birth (AFAB) (median age 21.5 years) and 37 assigned male at birth (AMAB) persons (median age 29 years) with data separated by a 1-year period.
Results: Testosterone therapy in AFAB persons led to a significant increase in VAT (P = 0.0006), trunk/limb ratio (P < 0.001), uric acid (P < 0.001), LDL-cholesterol (P < 0.05) and a significant decrease in HDL-cholesterol (P < 0.05). There were no changes in systemic inflammatory indices. Results of the final regression models indicated that increase in uric acid explained 33.2% of the variation in VAT [F(1,15) = 7.458; adjusted R square 0.332; P = 0.015]. In AMAB persons receiving GAHT, we observed an increase in total body fat (P = 0.002), fat mass index (P = 0.001) and HDL cholesterol (P < 0.05). The aspartate transaminase to lymphocyte ratio index decreased (P < 0.05) one year after the start of treatment.
Conclusion: GAHT in the AFAB persons led to a significant increase in VAT and altered metabolic profile. There were no changes in systemic inflammatory indices. The AMAB people presented a non-deleterious cardiometabolic phenotype.
Clinical trial registration: The study is registered at ClinicalTrials.gov (NCT04508231).
期刊介绍：
Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.
Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.
Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
